• Drug development is highly interconnected across the globe. The information technology that helps brings outsourced partners together also increases the risk of compromising intellectual property and network security.
• Merck and other leading drug companies, either individually or collectively (e.g. TransCelerate's Shared Investigator Platform) are managing these and related risks with systems based on technologies and standards assuring trust in the identities of participants. Mollie Shields-Uehling will explain current role of SAFE-BioPharma, the global identity and access management trust standard used in biopharmaceutical and healthcare.
• Andrew Porter, Merck, will describe EngageZone, Merck's collaborative research platform providing full accountability and security across its user community of CROs, clinical site staff, other pharmas, vendors, etc. IT safety features include single sign-on and access, multi-factor authentication, end-to-end encryption, multiple levels of access based on security provisioning, and user/role management. EngageZone is used to leverage big data analytics, proprietary applications, and multiple databases from access points across the globe.

Professionals who work in the area of:

• Regulatory Affairs
• Medical Affairs 
• Ethics
• Health Policy
• Digital Health Technology and Analytics 
• Post-marketing safety

At the conclusion of this on demand webinar, participants should be able to:

• Evaluate risk associated with Internet-based collaboration
• Discuss approaches to develop secure, trust-based information sharing
• Define critical terminology such as multi-factor authentication, federation, and identity and access management